Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia


Simsek E. T. , Eskazan A. E. , Cengiz M., Ar M. C. , Ekizoglu S., Salihoglu A., ...Daha Fazla

JOURNAL OF CLINICAL PATHOLOGY, cilt.69, ss.810-816, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 69 Konu: 9
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1136/jclinpath-2015-203320
  • Dergi Adı: JOURNAL OF CLINICAL PATHOLOGY
  • Sayfa Sayıları: ss.810-816

Özet

Aims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.